Dermatology and Hair Restoration: The Clinical Handoff Triggers That Signal When a Specialist Referral Is Needed

Introduction: One Continuum, Two Specialties

Patients facing hair loss often ask whether they should see a dermatologist or a hair restoration surgeon. That question rests on a false choice. Dermatology and hair restoration surgery are not competing disciplines; they are sequential phases of a single care pathway.

The premise is simple. Dermatologists diagnose hair loss and manage it medically. Hair restoration specialists take over once medical management has been fully explored and has reached its limits. The point where one hands off to the other should be a defined clinical decision rather than a guess.

This article examines four clinical handoff triggers that signal when that transition makes sense:

  1. A 12-month plateau on combination medical therapy
  2. Norwood and Ludwig staging thresholds
  3. Ruling out scarring alopecia and Diffuse Unpatterned Alopecia (DUPA)
  4. The 2026 shift toward JAK inhibitors for alopecia areata

Throughout, one idea holds steady: patients benefit most when they understand exactly when and why a dermatologist refers them onward, and what credentials to look for in the physician who receives that referral.

The Continuum of Care: Why Dermatology and Hair Restoration Work in Sequence

Dermatology is the specialty recognized by the American Board of Medical Specialties (ABMS) that covers the full spectrum of hair loss diagnosis. Dermatologists evaluate androgenetic alopecia, alopecia areata, scarring alopecias, telogen effluvium, and many other conditions. They also initiate first-line medical therapy.

Hair restoration surgery occupies a different position. It is not a separately recognized ABMS specialty. In the United States, any licensed physician can legally perform hair transplant surgery, regardless of underlying specialty or training. There is no residency, ABMS board, or state licensing requirement specific to hair transplantation. That gap makes the referral relationship, and the vetting of the receiving provider, especially consequential.

The two fields have always been intertwined. Norman Orentreich, a New York dermatologist, is credited with popularizing modern hair transplantation in the 20th century. The surgical discipline grew directly out of dermatology rather than in opposition to it.

Scale matters too. According to the American Academy of Dermatology, androgenetic alopecia affects an estimated 80 million Americans: 50 million men and 30 million women. With a population that large, a clear and efficient referral pathway between the two disciplines is a public health concern, not just a convenience.

A successful handoff, then, rests on a specific clinical decision point, not a vague sense that a patient “isn’t getting results.”

Handoff Trigger #1: The 12-Month Plateau on Combination Therapy

As of 2026, only two drugs are FDA-approved specifically for pattern hair loss:

  • Topical minoxidil, approved in 1988 for both men and women
  • Oral finasteride 1mg, approved in 1997 for men only

Dutasteride is also used off-label for androgenetic alopecia in the U.S., although its FDA approval covers only benign prostatic hyperplasia.

Combination therapy has become the standard before surgery is considered. A real-world UK study found that combined oral minoxidil plus finasteride produced stable or improved outcomes in 92.4% of 502 patients over 12 months. That figure explains why 12 months has become the clinically accepted window for judging response. Hair growth cycles are slow, and a shorter trial may not reveal a medication’s true effect.

During this window, a dermatologist is measuring several things:

  • Standardized photographic documentation at regular intervals
  • Density changes in affected regions
  • Shedding patterns, including whether shedding slows or stabilizes
  • Patient-reported satisfaction with appearance and progress

Timing cuts both ways. A premature referral, before the full 12-month trial, risks surgery on a scalp that could still respond to medical therapy. Waiting too long past a clear plateau carries its own risk: continued miniaturization of native hair and gradual depletion of the donor area that future surgery depends on.

Handoff Trigger #2: Norwood and Ludwig Staging Thresholds

Dermatologists rely on standardized frameworks to quantify hair loss. The Norwood-Hamilton scale classifies male pattern loss, from early temple recession to extensive crown and frontal loss. The Ludwig scale classifies female pattern loss, which typically presents as diffuse thinning across the crown with a preserved frontal hairline. These scales help determine when medical therapy alone is unlikely to restore acceptable density.

Staging does not work in isolation. It interacts with age and rate of progression. A patient who moves rapidly through stages despite consistent medication is a stronger surgical referral candidate than one who has remained stable at an early stage for years. A young patient at an advanced stage also raises different planning questions than an older patient whose pattern has settled.

Demand data reflects these dynamics. The 2025 ISHRS Practice Census shows surgical hair restoration patients are 84.7% male and 15.3% female. Female patient volume, however, is the fastest-growing segment, up 16.5% from 2021 to 2024. That growth reflects better diagnostic staging and greater referral awareness for Ludwig-scale patients. It also tracks with prevalence: roughly 12% of women experience hair loss by age 30, 25% by age 49, and 30% to 40% of women aged 60 to 69.

Staging thresholds are a guideline, not a rigid rule. The final decision also weighs donor supply, the patient’s goals, and overall candidacy.

Handoff Trigger #3: Ruling Out Scarring Alopecia and DUPA via Trichoscopy

Before any surgical referral, trichoscopy (dermoscopic examination of the scalp) should be considered a mandatory step. It differentiates non-scarring androgenetic alopecia from scarring, or cicatricial, alopecias. Scarring alopecias destroy follicles permanently, and patients with active disease are not surgical candidates. Transplanted grafts placed into an active inflammatory process are unlikely to survive.

A second distinction is just as important. Diffuse Unpatterned Alopecia (DUPA) is marked by diffuse follicular miniaturization across the entire scalp, including the occipital region at the back of the head. That region is the traditional donor zone. Because the donor hair itself is miniaturizing, DUPA patients are generally poor surgical candidates, even though they may appear at first glance to have straightforward pattern loss.

Recognizing DUPA often requires trichoscopy and densitometry expertise beyond general dermatologic screening. Published reappraisals of the diagnosis note that DUPA has been recognized largely by hair transplant surgeons, precisely because its effects on donor zones determine surgical eligibility. For that reason, ruling out DUPA works best as a shared diagnostic responsibility between the referring dermatologist and the receiving hair restoration specialist.

The stakes of getting this wrong are high. Harvesting grafts from a miniaturizing donor zone compromises both areas: transplanted hairs may thin over time, and the donor region can become visibly depleted. DUPA misdiagnosis is one of the most consequential handoff errors in the field.

Handoff Trigger #4: The 2026 Shift Toward JAK Inhibitors for Alopecia Areata

Alopecia areata is an autoimmune condition in which the immune system attacks hair follicles. It is clinically distinct from androgenetic alopecia and requires an entirely different treatment and referral logic.

Since 2022, the FDA has approved three JAK inhibitors for severe alopecia areata:

  • Olumiant (baricitinib), approved in 2022
  • Litfulo (ritlecitinib), approved in 2023 for patients down to age 12
  • Leqselvi (deuruxolitinib), approved in 2024

These medications work by suppressing the autoimmune signaling that drives the attack on follicles. In 2026, a Delphi consensus statement from the National Alopecia Areata Foundation and the American Hair Research Society, published in JAMA Dermatology, established oral JAK inhibitors as first-line therapy for adults with severe alopecia areata, with a preference for FDA-approved options.

This shift reshapes surgical appropriateness. JAK inhibitors can induce regrowth in follicles that were previously considered permanently dormant. As a result, surgery for alopecia areata patients is now typically deferred until medical response has been fully assessed, reversing older assumptions that long-standing patches were beyond medical help.

This is a new and evolving trigger category. It requires dermatologists and hair restoration specialists to coordinate more closely than ever, because premature surgery could waste limited donor grafts on a condition that medication alone may resolve.

What Happens After the Handoff: Why the Receiving Physician’s Credentials Matter

Once a dermatologist refers a patient for surgery, the regulatory reality becomes the patient’s concern. No U.S. state license or ABMS board specifically governs hair transplantation. Any licensed physician can legally perform the procedure, regardless of training.

The consequences are visible. In 2025, 59% of ISHRS members reported unlicensed or unsupervised “black market” clinics in their cities, up from 51% in 2021. Repair cases from these clinics now average about 10% of revision work. Verifying credentials after a referral is the patient’s responsibility.

The clearest objective marker is the American Board of Hair Restoration Surgery (ABHRS). Established in 1996, it is the only board certification focused exclusively on hair restoration surgery, and it is the credential recognized by the ISHRS.

The ABHRS Diplomate standard is demanding. Candidates must provide:

  • A 3-year documented safe-practice track record
  • 150 surgical logs documenting procedure type, graft count, and patient demographics
  • 50 operative reports
  • Before-and-after photographic evidence
  • Passage of both written and oral examinations

An alternative fellowship route requires 70 assisted cases plus 50 independent cases.

Only approximately 270 physicians worldwide currently hold ABHRS Diplomate status. That scarcity makes it the most useful single marker a dermatologist or patient can use to vet a surgical referral.

Completing the Continuum: What to Look for in a Receiving Hair Restoration Specialist

The ABHRS standard translates into a practical checklist for patients who have been referred:

  • Board status: Is the physician an ABHRS Diplomate?
  • Exclusive focus: How many years has the physician practiced hair restoration exclusively?
  • Procedure volume: How many procedures has the physician personally performed?
  • Documented outcomes: Are before-and-after results available for similar cases?

Dr. Glenn M. Charles of Charles Medical Group illustrates the credential profile this handoff calls for. He is a Diplomate and Past President of the American Board of Hair Restoration Surgery and served eight years on its Surgery Examination Committee. His practice has been limited exclusively to hair restoration for more than 25 years, and he has performed more than 15,000 procedures personally.

Additional markers of surgical rigor matter after referral, including trichoscopic candidacy evaluation at consultation, experience distinguishing DUPA from standard pattern loss, and familiarity with both FUE and FUT techniques, including robotic options. Charles Medical Group offers manual FUE, FUT, and the ARTAS robotic system; the practice was among the first in the world to acquire ARTAS technology.

Standing within the professional community is another signal. Charles Medical Group served as a Clinical Observation Center for Restoration Robotics, training surgeons from South America, Europe, and Asia. Dr. Charles is an annual faculty lecturer at the ISHRS conference, sits on the ISHRS Core Curriculum Committee, and has authored and edited the textbooks Hair Transplantation and Hair Transplant 360.

A well-credentialed receiving physician does more than execute surgery. That physician re-verifies the dermatologist’s staging and diagnostic findings before committing a patient’s limited donor supply to any procedure.

Conclusion: Treating the Handoff as a Clinical Decision, Not a Default

The four triggers form a coherent decision framework rather than isolated checkpoints:

  1. Plateaued medical response after a full 12-month trial
  2. Staging thresholds interpreted alongside age, progression, and donor supply
  3. Ruled-out contraindications, including scarring alopecia and DUPA
  4. Condition-appropriate escalation, with JAK inhibitors now reshaping alopecia areata pathways

The dermatology-to-hair-restoration handoff works best as a deliberate, criteria-based transition rather than a reflexive referral. Once that handoff occurs, credential verification, particularly ABHRS Diplomate status, becomes the patient’s safeguard in a field with no regulatory oversight specific to hair transplantation.

Good outcomes depend on both ends of the pathway: rigorous diagnosis on one end and verified surgical expertise on the other.

Scheduling the Next Step: A Consultation with Charles Medical Group

Patients who have plateaued on medical therapy, or who have been referred by a dermatologist for surgical evaluation, can schedule a complimentary consultation with Dr. Charles.

Consultations are available in person at the Boca Raton office (200 Glades Rd #2, Boca Raton, FL 33432) or the Brickell, Miami location. Out-of-state and international patients can meet with Dr. Charles through virtual consultations via FaceTime or Skype.

Patients choosing Charles Medical Group can expect:

  • An ABHRS Diplomate and Past President of the board
  • More than 25 years of practice focused exclusively on hair restoration
  • Personal involvement of Dr. Charles in the critical parts of every procedure
  • Transparent, no-pressure treatment planning with realistic expectations

For continuity of care, patients are encouraged to bring their dermatology records, medication history, progress photographs, and any trichoscopy findings to the consultation.

Consultations can be scheduled by calling 866-395-5544 or visiting charlesmedicalgroup.com.